Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.37 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753564 | 1.00 | DPP4 (0.44) | DPP4PIN1DPP7DPP8CYP3A4 | |
| SCHEMBL743824 | 1.00 | DPP4 (0.44) | DPP4PIN1DPP7DPP8CYP3A4 | |
| SCHEMBL30378432 | 1.00 | DPP4 (0.44) | DPP4PIN1DPP7DPP8CYP3A4 | |
| Tert-Butylamine SCHEMBL898670 | 0.94 | DPP4 (0.43) | DPP4PIN1DPP7DPP8CYP3A4 | |
| SCHEMBL13084120 | 0.89 | DPP4 (0.42) | DPP4DPP7DPP8CYP3A4NPC1 | |
| SCHEMBL6697319 | 0.88 | DPP4 (0.39) | DPP4PIN1DPP7CYP3A4NPC1 | |
| SCHEMBL344346 | 0.83 | CTRB1 (0.53) | DPP4PIN1 | |
| SCHEMBL344345 | 0.83 | CTRB1 (0.53) | DPP4PIN1 | |
| SCHEMBL15114869 | 0.82 | DPP4 (0.37) | DPP4DPP7DPP8CYP3A4NPC1 | |
| SCHEMBL15108794 | 0.82 | DPP4 (0.37) | DPP4DPP7DPP8CYP3A4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063351-B | Green synthesis of chiral beta amino acids using biological enzymes and immobilized aminotransferase used | 北京元延医药科技股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118063351-A | Green synthesis of chiral beta amino acids using biological enzymes and immobilized aminotransferase used | 北京元延医药科技股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117467733-B | High chiral purity sitagliptin and method for preparing same by using immobilized transaminase | 北京元延医药科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117467733-A | High chiral purity sitagliptin and method for preparing same by using immobilized transaminase | 北京元延医药科技股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-113121540-B | Synthesis method of sitagliptin free alkali | 鲁南制药集团股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-113121540-A | Synthesis method of sitagliptin free alkali | 鲁南制药集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-2802554-B1 | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS (SI) | 2018-04-25 | — | — | EP | disclosed |
| EP-2802554-B1 | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS (SI) | 2018-04-25 | — | — | EP | disclosed |
| EP-2802554-A1 | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF | LEK Pharmaceuticals d.d. (SI) | 2014-11-19 | — | — | EP | disclosed |
| EP-2481722-B1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2014-08-27 | — | — | EP | disclosed |
| CN-103694245-A | Crude medicine for hypoglycemic medicine | LI YOUXIANG | 2014-04-02 | — | — | CN | disclosed |
| WO-2013104774-A1 | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013104774-A1 | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2013-07-18 | — | — | WO | disclosed |
| EP-2615080-A1 | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof | LEK Pharmaceuticals d.d. (SI) | 2013-07-17 | — | — | EP | disclosed |
| EP-2615080-A1 | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof | LEK Pharmaceuticals d.d. (SI) | 2013-07-17 | — | — | EP | disclosed |
| US-8471057-B2 | Sitagliptin intermediates, preparation methods and uses thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2013-06-25 | — | — | US | disclosed |
| EP-2481722-A1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| US-20120178957-A1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2012-07-12 | — | — | US | disclosed |
| WO-2012042534-A2 | PROCESSES FOR THE PREPARATION OF R-SITAGLIPTIN AND INTERMEDIATES THEREOF | GLENMARK GENERICS LIMITED (IN) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012042534-A2 | PROCESSES FOR THE PREPARATION OF R-SITAGLIPTIN AND INTERMEDIATES THEREOF | GLENMARK GENERICS LIMITED (IN) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178957-A1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | DPP4, DPP8, DPP9 | DPP4 1/4885PIN1 977/4885DPP7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.